Posters

Clinical outcomes in patients following implantation of the Scharioth Macula Lens

Poster Details

First Author: B.Farago HUNGARY

Co Author(s):                        

Abstract Details

Purpose:

Retrospective evaluation of the clinical outcomes in three eyes of three pseudophakic patients with dry Age-related Macular Degeneration (AMD), wet AMD stabilized with anti-VEGF treatment, and Vitelliform Macular Dystrophy following the unilateral implantation of the novel A45SML plano powered supplementary intraocular lens with central +10.0 D addition (Scharioth Macula Lens; SML) manufactured by Medicontur.

Setting:

Central Sydney Eye Surgeons, Newtown, Sydney, Australia.

Methods:

All patients were evaluated prior to receiving the SML implant to ensure suitability for the procedure. Prediction of improvement in near visual acuity was simulated preoperatively by performing a near visual acuity test at a distance of 15cms from the patient’s eye with a +6.0 D addition in a trial frame over the distance correction of the patient. The SML was implanted into the ciliary sulcus of the better seeing eye in each case. Subjective refractions, uncorrected visual acuities at distance, best-corrected distance and near visual acuities, macula OCT and anterior segment OCT were tested preoperatively and postoperatively.

Results:

A significant improvement was noted with near visual acuity in the treated eye of each patient when tested at a reading distance of 15 to 18 cms (Patient 1 improved from 0.14 decimal acuity to 0.5; Patient 2 improved from 0.4 decimal acuity to 0.5. Patient 3 improved from 0.25 decimal acuity to 0.67). Most improvement was observed after postoperative visual training. The actual near visual acuities achieved were similar or even better compared to those estimated preoperatively. Distance visual acuity did not change in all cases. No complications related to the implantation or the lens itself were observed.

Conclusions:

The SML appears to be a safe option that can provide useful near vision in pseudophakic patients with maculopathies such as AMD and Vitelliform Macular Dystrophy.

Financial Disclosure:

None